SCHEMBL3014348

SCHEMBL3014348

COc1ccc(-c2csc(N3CCN(S(=O)(=O)c4ccc(OC)cc4OC)CC3)n2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.59
MAPT P10636 10/20 0.58
USP2 O75604 2/20 0.58
RECQL P46063 1/20 0.58
HSD17B10 Q99714 1/20 0.58
RAB9A P51151 3/20 0.57
NPC1 O15118 2/20 0.57
SMN1; SMN2 Q16637 7/20 0.53
ALDH1A1 P00352 5/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
LMNA P02545 6/20 0.53
MAPK1 P28482 5/20 0.53
TP53 P04637 3/20 0.52
TDP1 Q9NUW8 1/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
HTT P42858 2/20 0.50
ALOX15 P16050 1/20 0.50
GAA P10253 1/20 0.48
CYP1A1 P04798 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007277 0.95 MAPT (0.55) POLBMAPTUSP2RECQLHSD17B10
SCHEMBL3007441 0.94 MAPT (0.54) POLBMAPTUSP2RECQLHSD17B10
SCHEMBL3019064 0.94 MAPT (0.61) POLBMAPTUSP2RECQLHSD17B10
SCHEMBL3007685 0.93 MAPT (0.59) POLBMAPTUSP2RECQLHSD17B10
SCHEMBL3009594 0.93 MAPT (0.59) POLBMAPTUSP2RECQLHSD17B10
SCHEMBL3011711 0.93 MAPT (0.53) POLBMAPTUSP2RECQLHSD17B10
SCHEMBL3011469 0.93 MAPT (0.53) POLBMAPTUSP2RECQLHSD17B10
SCHEMBL3012041 0.92 POLB (0.59) POLBMAPTUSP2RECQLHSD17B10
SCHEMBL3007488 0.91 MAPT (0.56) POLBMAPTUSP2RECQLHSD17B10
SCHEMBL3013335 0.91 MAPT (0.56) POLBMAPTUSP2RECQLHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA POLB 4649/4885MAPT 18/4885USP2 1831/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.